Sells coronavirus vaccines to governments and commercial buyers, and supplies Matrix-M, a vaccine ingredient, to pharmaceutical partners.
10-K for FY2025, filed Feb 26, 2026In 2025 and continuing during the term of the Sanofi CLA, Sanofi will lead commercialization efforts for our COVID-19 Vaccine (Nuvaxovid™).…View ↗
Furthermore, we provide our Matrix-M™ adjuvant for use in collaborations. These include the R21/Matrix-M™ adjuvant malaria vaccine, a…View ↗
Product sales include sales associated with COVID-19 Vaccine supply agreements, sometimes referred to as advanced purchase agreements…View ↗
Governments and commercial buyers pay for COVID-19 vaccine doses, while partners pay for adjuvant and other materials when units are delivered. License fees are paid when rights are granted; milestones when achieved; royalties as licensed products sell, and service payments over time.
10-K for FY2025, filed Feb 26, 2026Product sales include sales associated with COVID-19 Vaccine supply agreements, sometimes referred to as advanced purchase agreements…View ↗
The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional…View ↗
The terms of the Company’s third-party licensing agreements may contain multiple performance obligations, including licenses, transition…View ↗
$1.1B
10-K for FY2025, filed Feb 26, 2026
$1.1B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
61%
FY2022: 78%
|
Product sales, FY2025
$685M Sources
|
Sold outright |
|
Licensing, royalties, and other
Mix
10-K for FY2025, filed Feb 26, 2026 |
39%
FY2022: 2.2%
|
Licensing, royalties, and other, FY2025
$438.4M Sources
|
Mix |
|
Grants
|
0.0%
FY2022: 19%
|
Grants, FY2025
$0 Sources
|
Governments buy vaccine doses under supply agreements. U.S. commercial doses move mainly through pharmaceutical wholesalers to retailers and health care providers; pharmaceutical partners buy adjuvant and other materials and license vaccine technology.
10-K for FY2025, filed Feb 26, 2026Product sales include sales associated with COVID-19 Vaccine supply agreements, sometimes referred to as advanced purchase agreements…View ↗
In the fourth quarter of 2023, the Company commenced sales of COVID-19 Vaccine to the U.S. commercial market. Product sales in the U.S. are…View ↗
Wholesale distributor fees, discounts, and chargebacks: The Company has arrangements under which indirect customers such as retailers…View ↗
The Company also has various arrangements that include a right for a customer to use the Company's intellectual property as a functional…View ↗
(2)Supply sales include commercial sales of COVID-19 Vaccine, adjuvant sales, and other material sales to the Company’s partners.View ↗
Yes. It kept 39 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$250.2M.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$31.4MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
Flat. Revenue was $1.1B in FY2025, about the same as the $1.1B of FY2021.
Vaccine commercialization shifts to partners
The earlier report describes Novavax as discovering, developing and commercializing vaccines; the latest says Sanofi leads Nuvaxovid commercialization while Novavax focuses on partnerships.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026Our corporate growth strategy focuses on maximizing the impact of our cutting-edge technology by forging partnerships for our Matrix-M…View ↗
In 2025 and continuing during the term of the Sanofi CLA, Sanofi will lead commercialization efforts for our COVID-19 Vaccine (Nuvaxovid™).…View ↗
In November 2025, we announced that we completed the transfer of the Nuvaxovid™ BLA to Sanofi, who remains responsible for further…View ↗
Matrix-M licensing expands
The earlier report emphasizes supplying Matrix-M for partner vaccines; the latest adds non-exclusive licenses allowing Sanofi and Pfizer to use the adjuvant in vaccine programs.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026We continue to evaluate commercial opportunities for the use of our Matrix-M™ adjuvant alongside vaccine antigens produced by other…View ↗
We continue to evaluate commercial opportunities for the use of our Matrix-M™ adjuvant alongside vaccine antigens produced by other…View ↗
In September 2025, we amended the Sanofi CLA to expand Sanofi's license to include use of Novavax's Matrix-M™ adjuvant in Sanofi's pandemic…View ↗
In January 2026, we entered into a License and Option Agreement with Pfizer Inc. (“Pfizer”) for use of our Matrix-M™. Under the terms of…View ↗
Pipeline broadens beyond infectious diseases
The earlier report centers on respiratory and emerging infectious diseases; the latest also describes exploring opportunities beyond infectious diseases.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Feb 26, 2026
Competes with Pfizer, Moderna, Sanofi, GSK, and Seqirus
10-K for FY2025, filed Feb 26, 2026A number of vaccine manufacturers, research institutions, and other organizations have developed a vaccine for SARS-CoV-2, the virus that…View ↗
Loading...